Orlistat in the treatment of obesity.
Orlistat in the treatment of obesity.
复制标题
DOI：
10.1517/14656566.1.4.841
复制
发表时间：
2000-05-01
影响因子：
3.2
通讯作者：
Ballinger, A
中科院分区：
文献类型：
--
作者：
Ballinger, A
奥利司他（Xenical，Hoffmann-La Roche）是胃肠道脂肪酶的强效抑制剂，因此可减少脂肪吸收。与其他减肥药物不同，它的吸收最低，对CNS没有影响。奥利司他适用于体重指数（BMI）至少为30 kg/m2或28 kg/m2且存在肥胖相关并发症（如高血压、糖尿病、高血压和阻塞性睡眠呼吸暂停）的患者。在临床试验中，奥利司他（120 mg t.i.d.）与仅用饮食治疗的患者相比，与生活方式改变和低热量饮食（30%的能量来自脂肪）相结合，诱导了显著更多的体重减轻和改善的肥胖症的健康并发症（糖尿病、高血压、高血脂症）。与脂肪吸收不良相关的副作用，在治疗的第一年内发生在超过20%的受试者中，包括油性粪便斑点、腹痛、排气和脂肪/油性粪便。奥利司他的副作用在治疗的第二年减少了。奥利司他治疗患者的脂溶性维生素血浆浓度降低，但通常不会低于正常范围。没有研究评估奥利司他的疗效或超过两年的副作用。
Orlistat (Xenical, Hoffmann-La Roche) is a powerful inhibitor of gastrointestinal lipase and as such, reduces fat absorption. Unlike other weight-reducing drugs it is minimally absorbed and has no effects in the CNS. Orlistat is indicated for patients with a body mass index (BMI) of at least 30 kg/m2 or 28 kg/m2 in the presence of obesity-associated complications, such as hypertension, diabetes mellitus, hyperlipidaemia and obstructive sleep apnoea. In clinical trials, orlistat (120 mg t.i.d.) in combination with life-style modification and a hypocaloric diet (30% of energy from fat) induced significantly more weight loss and improved health complications of obesity (diabetes, hypertension, hyperlipidaemia) compared to patients treated with diet alone. Side effects related to fat malabsorption, occurred in more than 20% of subjects during the first year of treatment and included oily faecal spotting, abdominal pain, flatus with discharge and fatty/oily stool. Side effects from orlistat diminished in the second year of treatment. Plasma concentrations of fat soluble vitamins decreased in orlistat-treated patients but did not usually fall below the normal range. No studies have evaluated the efficacy of orlistat or side effect profile beyond two years.